"Just one patient survived." Yes, but dosage was suboptimal and since these were MSS patients, I assume that unlike the 5 mTNBC survivors, they were not given a checkpoint inhibitor since ICI's don't do much alone in MSS colorectal patients. I am very anxious to see if LL raises the PD-L1 level in the new CRC trial and, if so, to see the results of then dosing those patients with an ICI.

What little I've learned on these topics I got from reading this board and otherwise have no background in medical science. If I have stated things incorrectly, I would be glad to see corrections from the more knowledgeable posters here. GLTAL, Ganesha